When policymakers talk about “drug price controls,” it’s often framed as a commonsense solution to rising health care costs. I understand that impulse. As a former Pennsylvania legislator, and, as a breast cancer survivor, I know firsthand how stressful and expensive serious illness can be.
But good intentions don’t guarantee good outcomes. Proposals like “Most Favored Nation” (MFN) drug pricing may sound simple, but for cancer patients, they carry serious risks that deserve closer scrutiny.
Read more: Drug price controls sound good until you’re the cancer patient they leave behind | Opinion
